Bladder carcinomas and normal urothelium universally express gp200-MR6, a molecule functionally associated with the interleukin 4 receptor (CD 124). by Tungekar, M. F. et al.
Bridsh Journal of Cancer (1996) 73, 429-432
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 iw
Bladder carcinomas and normal urothelium universally express
gp200-MR6, a molecule functionally associated with the interleukin 4
receptor (CD 124)
MF Tungekarl, KC Gatter2 and MA Ritter3
'Division ofHistopathology, United Medical and Dental Schools ofGuy's and St Thomas' Hospitals Trust, Lambeth
Palace Road, London SEI 7EH, UK; 2Nuffield Department ofPathology, John Radcliffe Hospital, Headington, Oxford
OX3 9DU, UK; 3Department ofImmunology, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road,
London W12 ONN, UK.
Summary Monoclonal antibody MR6 detects gp200-MR6, a molecule functionally associated with the
interleukin 4 (IL-4) receptor. Positive immunolabelling with MAb MR6 was obtained in 28/28 transitional cell
carcinomas of the bladder, representing a range of different grades and stages of disease, as well as in all
control non-neoplastic urothelia. The expression of mutant p53 protein and epidermal growth factor receptor
was detected in 14/28 and 20/28 cases respectively. Proliferation indices, determined by Ki67 labelling, ranged
from 5% to 95% among these tumours. The universal expression of gp200-MR6 in neoplastic and non-
neoplastic urothelium has important implications for the possible use of IL-4 in tumour therapy and suggests
that IL-4 may play a role in differentiation and homeostasis of urothelium and other mucosal epithelia.
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Adoptive immunotherapy of tumours using cytokines to
promote an anti-tumour response mounted by lymphocytes,
macrophages and killer cells has attracted a great deal of
attention in recent years (Colombo and Forni, 1994). Much
of this effort has been directed at interleukin 2 (IL-2). When
used alone for this purpose it is effective for only a few
tumour types and carries risks of severe toxic reactions
(Bukowski et al., 1993). Other members of the interleukin
family also hold much promise, given the known interactions
amongst the various cytokines (Jansen et al., 1990; Colombo
and Forni, 1994). Interleukin 4 (IL-4), the product of a
subset of T lymphocytes (Th2), was initially believed to be a
B-cell growth factor but is now known to have potent
regulatory effects on haemopoietic cells of various lineages
and regulates many of the effects of IL-2 (Jansen et al., 1990;
Paul, 1991; Isakson, 1992; Paul and Seder, 1994). Therefore,
there is much enthusiasm about potential uses of IL-4 in this
field (Lotze et al., 1990; Costello et al., 1993; Tepper et al.,
1993), especially since it potentiates the anti-proliferative
effects of tumour necrosis factor a and interferon y on
neoplastic cell lines, may itself have such effects and is
tumoricidal in murine models (Totpal et al., 1991; Redmond
et al., 1992; Topp et al., 1993).
IL-4 mediates its biological effects by binding to a specific
receptor present on the surface of target cells, which is a
member of the haematopoietin receptor family (Keegan and
Pierce, 1994). The IL-4 receptor (IL-4R), which comprises the
IL-4 binding component (CD124) together with the common
y-chain (yc) is expressed by B and T lymphocytes,
macrophages and mast cells (Jansen et al., 1990; Russel et
al., 1993). Increasingly however its presence is being reported
on non-haemopoietic cells such as cell lines derived from
melanoma and various epithelial tumours (Morisaki et al.,
1992; Toi et al., 1992; Obiri et al., 1993, 1994).
The monoclonal antibody (MAb) MR6 was raised against
human thymic cortical epithelial cells but was also found to
show weaker reactions with lymphocytes, dendritic cells,
macrophages and some non-thymic epithelia (DeMaagd et
al., 1985; von Gaudecker et al., 1995). Subsequent
investigations showed that MAb MR6 detects a 200 kDa
glycoprotein (gp200-MR6) and that addition of the MAb to
in vitro assays blocks IL-4-induced proliferation of cloned T
cells and the IL-4-dependent switch to IgE in allergen-
stimulated B cells, and may inhibit the development and
expansion of IL4-secreting 'Th2' T helper cells; these data
indicate that gp200-MR6 is functionally associated with the
IL-4R, although MAb MR6 does not interfere with the
binding of IL-4 to the CD124 ligand-binding chain of the
receptor (Larche et al., 1988; Mat et al., 1990; Imami et al.,
1994).
We have previously used MAb MR6 to demonstrate the
presence of gp200-MR6 in surgically resected breast,
pulmonary and colorectal carcinomas (Mat et al., 1990;
Tungekar et al., 1991; Kaklamanis et al., 1992). However, not
all tumours were gp200-MR6 positive, and a subsequent
detailed analysis of breast tumours showed that loss of this
molecule was associated with higher grade tumours (Mat et
al., 1993). These observations not only suggest that gp200-
MR6 expression may be useful in prognostic evaluation, but
also raise the possibility of direct effects of IL-4 on epithelial
tumours in addition to its recognised immunoregulatory
influences on the cells infiltrating the tumour stroma.
Intravesical immunotherapy with BCG is a well-estab-
lished method of treatment for superficial transitional cell
carcinomas of the bladder (Ozen, 1993). For advanced forms
of these tumours arterial infusion of recombinant interleukin
2 (rIL-2) with lymphokine-activated killer cells has been tried
with mixed results (Hermann et al., 1992). The application of
IL-4 in this area is likely to be explored in future in view of
the synergistic effects it shares with other cytokines. For this
reason a study of IL-4R and gp200-MR6 expression in
transitional cell carcinomas of bladder is particularly
relevant.
We have therefore used MAb MR6 to investigate the
expression of gp200-MR6 in a series of 28 resected urothelial
bladder carcinomas of various grades and stages. Our data
reveal that it is universally expressed by these tumours and by
non-neoplastic urothelium. In contrast, the tumours were
heterogeneous in their expression of epidermal growth factor
receptors (EGFRs) and mutant p53, and exhibited a broad
range of proliferative grades as determined by Ki67 staining.
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Materials and methods
Blocks from 28 consecutive surgically excised bladder
tumours were snap frozen and stored in liquid nitrogen.
The tumour types were classified according to the World
Health Organization Classification (Mostofi et al., 1973) and
staged according to UICC guide lines (International Union
Against Cancer, 1987). The tumours were all transitional cell
carcinomas; of these, 12 were grade 2, and 16 grade 3.
Depths of invasion and grades are summarised in Table I.
Twelve specimens of non-neoplastic urothelium were avail-
able as controls: five of these were excised with tumours and
the rest obtained at cystoscopic examination that turned out
to be substantially normal.
The primary MAb antibodies used are indicated in Table
II. All are murine IgGI reagents except EGFR1 which
belongs to the IgG 2 class. Staining with Ki67 was carried
out to study the proliferation rates and to assess the general
state of preservation of antigens since the Ki67 antigen is
highly sensitive to degradation.
Immunohistochemical staining was performed using the
alkaline phosphatase-anti-alkaline phosphatase procedure as
described previously (Cordell et al., 1984). No staining was
observed when the primary antibody was omitted or when it
was replaced by an irrelevant isotype-matched monoclonal
antibody (Figure 1).
Results
A total of 28/28 transitional cell carcinomas of the bladder
expressed the gp200-MR6. Nearly all the cells within these
tumours stained with the MAb MR6, although the intensity
of the staining varied from moderate to strong with different
areas of each tumour (Figure 2). The staining was mostly
concentrated on the cell surfaces and was more intense at the
periphery of tumour masses than at their centre. However the
intensity of immunoreactivity showed no significant relation-
ship to the grades or stages of the tumours (Figure 3). The
results of immunostaining for EGFR and p53 positivity are
summarised in Table III. EGFR and p53 positivity were seen
in 20/28 and 14/28 cases respectively. The Ki67 positivity rate
of the individual tumours ranged from 5% to 95%.
In all the control specimens, non-neoplastic urothelium
showed labelling with MAb MR6, with more intense staining
of the basal layers and hyperplastic von Brunn's nests (Figure
4). The lymphoid cells infiltrating the tumour stroma were
strongly labelled with MAB MR6 (Figure 3).
Table I Stages and grades of tumours
Depth ofinvasion Grade a Stage b
Non-invasive, G2 (n = 11) pTa (n =11)
papillary (n = 11)
Tunica propria (n=9) G2 (n=5), G3 (n=4) pTI (n=9)
Muscularis propria G3 (n=8) pT2 (n =8)
(n=8)
aAccording to WHO Classification of bladder tumours (Mostofi et
al., 1973). bAccording to UICC staging protocol for bladder tumours
(International Union Against Cancer, 1987).
Table II The antibody panel used
Antibody Specificity Source
MR6 gp200-MR6 MA Ritter
EGFR1 Epidermal growth Dako
factor receptor
Ki67 Proliferation- Dako
associated antigen
NCL-p53-1801 Amino acids 32-79 of Novocastra
p53 protein
The importance of IL-4 as a potent regulatory molecule for
haemopoietic cells and its modulatory influence over the
effects of other cytokines are well established (Jansen et al.,
1990). Its use in the adoptive immunotherapy of tumours is
therefore being advocated (Lotze et al., 1990; Costello et al.,
Figure 1 Negative control for alkaline phosphatase immunos-
taining. No labelling was seen when the primary antibody was
replaced by an isotype matched control. (Light haematoxylin
nuclear counterstain). Magnification, x 120.
Figure 2 A grade II, stage pTl transitional cell carcinoma
stained with MAb MR6 shows varying degrees of labelling of
tumour cells (t), however the staining is more intense at the cell
surfaces as well as along the periphery of tumour cell masses at
their interface with stroma (s). Alkaline phosphatase immunos-
taining. Magnification, x 120.
Figure 3 A transitional cell carcinoma of similar grade and stage
to the tumour in Figure 2 shows weaker labelling with MAb
MR6. Note the intense labelling of an aggregate of stromal
lymphoid cells (arrow). Alkaline phosphatase immunostaining.
Magnification, x 120.
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Figure 4 The non-neoplastic control specimen shows labelling of
the surface urothelium (u) as well as of von Brunn's nests (large
arrow heads) with MAb MR6. Occasional lymphoid cells in the
stroma (small arrow heads) are also labelled. Alkaline
phosphatase immunostaining. Magnification, x 120.
Table III Pattern of EGFR and p53 staining in 28 cases
Antigen EGFR-positive EGFR-negative
p53 positive 9 5
p53 negative 11 3
1993; Tepper et al., 1993). Topical immunotherapy with BCG
is of proven value in superficial but not deeply invasive or
metastatic urothelial carcinomas of the bladder (Ozen, 1993).
Treatment of advanced carcinomas of these types with
infusions of rIL-2 with lymphokine-activated killer (LAK)
cells has not had much success and also has toxic side-effects
(Hermann et al., 1992; Ozen, 1993). Recombinant IL-4 (rIL-
4) enhances the proliferation of tumour infiltrating lympho-
cytes (TILs) and macrophages induced by IL-2 in bladder
carcinomas (Kawakami et al., 1993), and therefore appears to
be a logical addition to IL-2 in treatment of these tumours.
Our demonstration that gp200-MR6, which is functionally
associated with the IL-4R, is expressed on neoplastic
urothelium and other epithelia raises important questions
about such possible therapeutic applications of IL-4 (Larche
et al., 1988; Mat et al., 1990; Tungekar et al., 1991;
Kaklamanis et al., 1992; Mat et al., 1993; Imami et al.,
1994). The IL-4R expressed by carcinomas are likely to be
functionally active since in vitro studies have shown their
ability to bind IL-4 with subsequent internalisation of IL-4-
IL-4R complex (Morisaki et al., 1992; Toi et al., 1992; Obiri
et al., 1993). Thus IL-4, besides modifying the activities of
host cells infiltrating the tumours, may directly influence
growth of tumour cells. In vitro studies have shown that IL-4
alone may induce either inhibition or promotion of growth in
cell lines derived from various tumours (Totpal et al., 1991;
Morisaki et al., 1992, 1994; Toi et al., 1992; Obiri et al., 1993,
1994). Clinical studies of certain subsets of breast cancers
suggest that cytokines released from host cells infiltrating
tumour stroma may act in a paracrine fashion to promote
growth of neoplastic cells and that cytotoxic therapy is
beneficial because of its immunosuppressive effects (Stewart
and Tsai, 1993). The expression of gp200-MR6 by non-
neoplastic urothelium as well as all the urothelial carcinomas
may point to a fundamental physiological role for IL-4 in
homeostasis of this tissue that is retained in its neoplastic
transformation.
The finding that all bladder carcinomas express gp200-
MR6 is in contrast to the selective pattern of expression of
this molecule in tumours of lung, breast, colon and rectum
(Mat et al., 1990, 1993; Tungekar et al., 1991; Kaklamanis et
al., 1992). Thus approximately 35% of all non-small-cell
carcinomas of the lung and 30% of breast carcinomas were
positive for gp200-MR6, whereas all colorectal adenomas and
90% of carcinomas expressed the antigen (Mat et al., 1990,
1993; Tungekar et al., 1991; Kaklamanis et al., 1992).
Moreover, loss of gp200-MR6 in carcinoma of the breast
has been shown to be associated with increased malignancy
(Mat et al., 1993). The retention ofgp200-MR6 expression by
all transitional bladder cell carcinomas may give the
impression that the cohort of tumours in the present study
was biologically homogeneous. That this is unlikely to be the
case is illustrated by the obvious heterogeneity ofthe tumours
in terms of known markers of biological behaviour such as
grade, stage, proliferative activity determined by Ki67
labelling, and expression of EGFR and mutant p53. These
observations indicate that IL-4 may play a role in
maintaining the integrity of transitional epithelium even in
its neoplastic state and that gp200-MR6 expression is unlikely
to be useful in predicting the biological behaviour of bladder
tumours. Moreover, while it should be possible to use
antibodies such as MR6 with radioisotopic tags for
visualisation of primary and metastatic disease in urothelial
carcinomas, as previously shown for the lung, the presence of
IL-4R on normal epithelia would argue against the use of
chimaeric toxin-IL-4 conjugates to target IL-4R positive
tumours because ofthe risks of epithelial damage (Al Jabaari
et al., 1989; Lakkis et al., 1991; Debinski et al., 1993).
In conclusion, this study, by demonstrating gp200-MR6
on normal and neoplastic urothelium, has further extended
the list of target cells that may be susceptible to the influence
of IL-4 and has raised new issues regarding the application of
this versatile cytokine in adoptive immunotherapy of
tumours. It has also highlighted the possible physiological
influence of IL-4 on epithelia and emphasises the importance
of studying the expression of receptors in surgical biopsy
material in addition to the in vitro studies performed on cell
lines and in animal models.
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